Lyka Labs Hits 52-Week Low, Trading at Rs 90.2

Lyka Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by touching its 52-week low of Rs 90.20 on October 9, 2025. This marks a notable decline, as the stock is currently 4.06% away from this low point. Over the past year, Lyka Labs has experienced a substantial drop in value, with a performance decline of 33.44%, contrasting sharply with the Sensex's modest gain of 0.87%.
Today, Lyka Labs underperformed its sector by 2.37%, continuing a trend of trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. The company's financial metrics reveal a high debt-to-equity ratio of 2.75 times, indicating a significant leverage position. Despite these challenges, Lyka Labs has shown strong management efficiency, with a return on capital employed (ROCE) of 17.59% and consistent operating profit growth at an annual rate of 33.02%.

As the market closes, the Nifty index stands at 25,181.80, reflecting a gain of 0.54%, while all market cap segments, particularly mid-caps, are experiencing upward momentum.